DXCM vs EMBC
DXCM: Dexcom is a leader in continuous glucose monitoring (CGM) technology, providing essential real-time health data for diabetes management and metabolic health. EMBC: A dedicated diabetes care company specializing in insulin delivery systems and pen needles for millions of users worldwide.
Side-by-side fundamentals
| Metric | DXCM | EMBC | Edge |
|---|---|---|---|
| Price as of 2026-07-22 close | $71.43 | $3.25 | |
| Market cap as of 2026-07-23 | $28.8B | $193M | |
| P/E as of 2026-07-23 | 31.00 | 1.72 | EMBC lower |
| PEG as of 2026-07-23 | 1.26 | -0.17 | EMBC lower |
| Net margin as of 2026-07-23 | +19.3% | +10.7% | DXCM higher |
| Gross margin as of 2026-07-23 | +63.4% | +61.9% | DXCM higher |
| Operating margin as of 2026-07-23 | +21.4% | +25.8% | EMBC higher |
| ROE as of 2026-07-23 | +33.8% | +6.1% | DXCM higher |
| ROA as of 2026-07-23 | +13.4% | +10.3% | DXCM higher |
| Debt / equity as of 2026-07-23 | 0.44 | 0.00 | EMBC lower |
| Revenue growth (YoY) as of 2026-07-23 | +16.1% | -3.4% | DXCM higher |
| Revenue CAGR (3y) SEC XBRL | +17.0% | -1.5% | DXCM higher |
| Dividend yield as of 2026-07-23 | n/a | +1.2% | |
| Dividend streak (yrs) SEC XBRL | n/a | 4 | |
| Beta as of 2026-07-23 | 1.42 | 0.84 | |
| 1-year return as of 2026-07-22 close | -11.0% | -67.2% | DXCM higher |
Fundamentals: Finnhub, as of 2026-07-23. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-22.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.